AUA 2018: Prostate Cancer: What PET to GET?

San Francisco, CA (UroToday.com) Thomas Hope, MD presented the different PET radiotracers available today for prostate cancer.  He began with the NaF PET/CT. This radiotracer has a good spatial resolution, high signal to the background with CT available for correlation, and has a short time from injection to imaging. Imaging is usually done 60 minutes after injection compared to 3 hours with bone scans.

Another PET radiotracer is Choline, which is used in the setting of biochemical recurrence. This has been FDA approved since 2011. Choline is a component of cell membranes. Despite having good specificity and sensitivity, there is limited detection sensitivity when PSA < 2 ng/ml. 

FACBC-Fluciclovine is taken up by two amino acid transporters that are upregulated in prostate cancer cells. It has been shown to outperform C11 Choline, and has been FDA approved since June 2016 (Figure 1).

Figure 1:
Fuciclovine

Ga-68 PSMA-11 prostate specific membrane antigen is probably the best PET modality to date for prostate cancer. It binds the extracellular domain (as opposed to ProstaScint that was bound to the intracellular domain). It has been demonstrated to have a higher sensitivity than fluorocholine in patients with biochemical recurrence. PSMA is currently being used worldwide with more and more countries using it for different stages of prostate cancer disease.

Lastly, F-DCFPyL, which is termed the PyL compound, has low blood pool activity and is currently in phase 2/3 trials.

In summary, there are a growing number of radiotracers. Fluciclovine is FDA approved, widely available and reimbursed by Medicare. PSMA PET has a higher detection sensitivity but is limited to the research setting in the USA.


Presented by: Thomas Hope, MD, Chief of MRI and Nuclear Medicine, San Francisco VA Medical Center

Written by:  Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe